Get the Stockscreener App
162.70
1.26%
-2.07
Pre-market:
161.91
-0.79
-0.49%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $162.70, with a volume of 3.07M.
It is down -1.26% in the last 24 hours and up +4.55% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$164.77
Open:
$162.82
24h Volume:
3.07M
Relative Volume:
1.00
Market Cap:
$252.33B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
48.86
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.00%
1M Performance:
+4.55%
6M Performance:
-19.27%
1Y Performance:
+98.95%
1-Day Range:
$161.13
$163.78
1-Week Range:
$160.87
$165.74
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
162.70 | 255.11B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca PLC : Barclays maintains a Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 0.3 percent gain - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
AstraZeneca stock gains on FDA breast cancer approval and analyst support - AD HOC NEWS
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - The Globe and Mail
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval - Proactive financial news
AstraZeneca stock gains on analyst support and July results - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Back in Focus After Fresh Regulatory News? - Kalkine Media
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer - pharmaceutical-technology.com
AstraZeneca's breast cancer drug granted accelerated approval in the US - Sharecast.com
AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com
AstraZeneca’s Etcamah Approved In US For ESR1-mutated Advanced Breast Cancer - DirectorsTalk Interviews
REGAstraZeneca PLCEtcamah approved in the US for HR+ breast cancer - tradingview.com
A green light from the US FDA for AstraZeneca in breast cancer - marketscreener.com
AstraZeneca PLC : Jefferies reaffirms its Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 1.15 percent drop - AD HOC NEWS
IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo - London South East
AstraZeneca stock reacts as FDA grants accelerated approval for new breast cancer pill - AD HOC NEWS
AstraZeneca's Etcamah Combination Authorized for Advanced Breast Cancer Treatment in US - marketscreener.com
AstraZeneca’s breast cancer pill gets FDA approval - The Seattle Times
AstraZeneca's Breast Cancer Pill Gets Approval From The FDA - NDTV Profit
FDA Clears AstraZeneca's Breast Cancer Pill Etcamah - Briefs Finance
AstraZeneca’s Breast Cancer Pill Gets Approval From the FDA - Bloomberg.com
AstraZeneca wins approval of camizestrant for breast cancer (NYSE:AZN) - Seeking Alpha
AstraZeneca slides Friday, underperforms market - MarketWatch
AstraZeneca: Share price weakness of late, should be capitalised on - marketscreener.com
AstraZeneca settles Texas case for $34 million - BioXconomy
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power - Yahoo Finance
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
Key facts: AstraZeneca PLC buys ZEGFROVY; EU OK Enhertu; Tagrisso PFS - tradingview.com
AstraZeneca (AZN) lifts share count to 1.55B after employee share issues - Stock Titan
All AstraZeneca (AZN) shares carry votes on 1.55B total - Stock Titan
AstraZeneca acquires ZEGFROVY rights for $600 million - grafa.com
AstraZeneca lists €2.55B euro notes in London | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca gets EU OK for Enhertu 1st-line breast cancer | AZN SEC FilingForm 6-K - Stock Titan
Wan Ling Martello to join AstraZeneca (AZN) board in 2026, bringing experience from Nestlé, Walmart and Alibaba. - Stock Titan
AstraZeneca pays $600m for global Zegfrovy rights | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca lung cancer combo extends time to progression | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca unveils Zegfrovy deal, lung trial win and Enhertu approval - marketscreener.com
AstraZeneca subsidiary lists €2.55bn bonds on LSE - Investing.com
AstraZeneca PLC : JP Morgan reaffirms its Buy rating - marketscreener.com
AstraZeneca and HUTCHMED report Phase III results for Tagrisso-Orpathys combination - Yahoo Finance UK
AstraZeneca PLC (AZN) Stock Analysis: Unraveling a 30.63% Potential Upside Within the Healthcare Sector - directorstalkinterviews.com
AstraZeneca Completes License Agreement for Lung Cancer Treatment - marketscreener.com
AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer - astrazeneca.com
AstraZeneca Loses Suit Seeking Block on Colorado Pharmacy Law - Bloomberg Government News
AstraZeneca (AZN) Tezspire improves swallowing symptoms in Phase III trial - Stock Titan
AstraZeneca slides Wednesday, underperforms market - MarketWatch
AstraZeneca (AZN) lines up €2.55B in new Eurobonds - Stock Titan
Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT - tradingview.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):